These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11893885)

  • 1. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.
    Stemmler J; Weise A; Hacker U; Heinemann V; Schalhorn A
    Onkologie; 2002 Feb; 25(1):60-3. PubMed ID: 11893885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
    Vénat-Bouvet L; Saint-Marcoux F; Lagarde C; Peyronnet P; Lebrun-Ly V; Tubiana-Mathieu N
    Anticancer Drugs; 2007 Sep; 18(8):977-80. PubMed ID: 17667606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
    Shimonov M; Hayat H; Chaitchik S; Brener J; Schachter P; Czerniak A
    Chemotherapy; 2005 May; 51(2-3):111-5. PubMed ID: 15886466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
    van Riel JM; van Groeningen CJ; Kedde MA; Gall H; Leisink JM; Gruia G; Pinedo HM; van der Vijgh WJ; Giaccone G
    Clin Cancer Res; 2002 Feb; 8(2):405-12. PubMed ID: 11839656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer].
    Shinozaki E; Mizunuma N; Tanabe M; Chin K; Ota K; Ohkochi N; Hatake K
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):397-9. PubMed ID: 15791826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
    Bhutiani N; Akinwande O; Martin RC
    World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.
    van Riel JM; van Groeningen CJ; de Greve J; Gruia G; Pinedo HM; Giaccone G
    Ann Oncol; 2004 Jan; 15(1):59-63. PubMed ID: 14679121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: results of an extended phase I study.
    Eichler K; Dufas T; Hammerstingl R; Gruber-Rouh T; Vogl TJ; Zangos S
    Chemotherapy; 2013; 59(1):66-73. PubMed ID: 23839050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis.
    Budakoglu B; Abali H; Uncu D; Yildirim N; Oksüzoglu B; Zengin N
    J Chemother; 2005 Aug; 17(4):452-3. PubMed ID: 16167527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
    Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases--a pilot experience.
    Melichar B; Dvorák J; Jandík P; Tousková M; Malírová E; Megancová J; Voboril Z
    Hepatogastroenterology; 2001; 48(42):1721-6. PubMed ID: 11813608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors.
    Karaoğlu A; Yalcin S; Tekuzman G; Kars A; Celik I; Güler N; Ozişik Y; Türker A; Barişta I; Güllü I
    Tumori; 2003; 89(2):141-5. PubMed ID: 12841660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
    Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
    Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
    Said R; Kurzrock R; Naing A; Hong DS; Fu S; Piha-Paul SA; Wheler JJ; Janku F; Kee BK; Bidyasar S; Lim J; Wallace M; Tsimberidou AM
    Invest New Drugs; 2015 Aug; 33(4):911-20. PubMed ID: 25990659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
    Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW
    Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.